| Index | S&P 500 | P/E | 42.73 | EPS (ttm) | 29.80 | Insider Own | 10.28% | Shs Outstand | 941.36M | Perf Week | 1.31% |
| Market Cap | 1.20T | Forward P/E | 26.92 | EPS next Y | 47.31 | Insider Trans | -0.03% | Shs Float | 848.41M | Perf Month | 7.75% |
| Enterprise Value | 1.24T | PEG | 2.29 | EPS next Q | - | Inst Own | 82.40% | Short Float | 0.83% | Perf Quarter | 6.34% |
| Income | 26.71B | P/S | 15.05 | EPS this Y | 44.34% | Inst Trans | 0.00% | Short Ratio | 2.79 | Perf Half Y | 44.06% |
| Sales | 79.67B | P/B | 35.38 | EPS next Y | 38.95% | ROA | 18.77% | Short Interest | 7.04M | Perf YTD | 18.50% |
| Book/sh | 35.99 | P/C | 133.94 | EPS next 5Y | 18.68% | ROE | 92.58% | 52W High | 1321.15 -3.61% | Perf Year | 56.75% |
| Cash/sh | 9.51 | P/FCF | 59.78 | EPS past 3/5Y | 51.73% 28.82% | ROIC | 31.00% | 52W Low | 806.04 57.99% | Perf 3Y | 109.71% |
| Dividend Est. | 6.92 (0.54%) | EV/EBITDA | 28.74 | Sales past 3/5Y | 31.69% 21.58% | Gross Margin | 83.40% | Volatility | 2.94% 2.85% | Perf 5Y | 435.34% |
| Dividend TTM | 6.69 (0.53%) | EV/Sales | 15.62 | EPS Y/Y TTM | 154.48% | Oper. Margin | 49.72% | ATR (14) | 38.23 | Perf 10Y | 1491.83% |
| Dividend Ex-Date | Aug 14, 2026 | Quick Ratio | 1.00 | Sales Y/Y TTM | 76.87% | Profit Margin | 33.53% | RSI (14) | 62.22 | Recom | 2.33 |
| Dividend Gr. 3/5Y | 15.24% 15.18% | Current Ratio | 1.35 | EPS Q/Q | 32.81% | SMA20 | 5.69% | Beta | 0.41 | Target Price | 1355.25 |
| Payout | 21.66% | Debt/Eq | 1.60 | Sales Q/Q | 47.67% | SMA50 | 7.32% | Rel Volume | 0.90 | Prev Close | 1306.69 |
| Employees | 50,000 | LT Debt/Eq | 1.54 | Earnings | Oct 29 | SMA200 | 17.38% | Avg Volume | 2.51M | Price | 1273.46 |
| IPO Date | Jun 01, 1972 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 30.92% 10.33% | Net Debt/EBITDA | 1.06 | Volume | 2,261,050 | Change | -2.54% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-21-26 | Reiterated | Leerink Partners | Outperform | $1232 → $1316 |
| Oct-20-26 | Reiterated | Goldman Sachs | Buy | $1.00 → $1413 |
| Oct-08-26 | Reiterated | Cantor Fitzgerald | Overweight | $1410 → $1440 |
| Oct-07-26 | Reiterated | Morgan Stanley | Overweight | $1419 → $1430 |
| Sep-18-26 | Reiterated | Guggenheim | Buy | $1273 → $1284 |
| Sep-15-26 | Reiterated | Berenberg Bank | $1135 → $1400 | |
| Sep-10-26 | Reiterated | HSBC | Reduce | $1251 → $940 |
| Aug-07-26 | Reiterated | UBS | Buy | $1.00 → $1376 |
| Aug-06-26 | Reiterated | Morgan Stanley | Overweight | $1.00 → $1419 |
| Aug-06-26 | Reiterated | BMO Capital | Outperform | $1300 → $1400 |
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 79,666 | 65,179 | 45,043 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 13,225 | 11,052 | 8,418 | — | — | — | — | — | — | |
| Gross Profit | 66,441 | 54,127 | 36,625 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 12,236 | 11,094 | 8,594 | — | — | — | — | — | — | |
| Research and Development | 14,597 | 13,337 | 10,991 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 39,608 | 29,696 | 17,040 | — | — | — | — | — | — | |
| Interest Expense | 980 | 795 | 781 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -5,033 | -3,170 | -3,579 | — | — | — | — | — | — | |
| Net Income Before Taxes | 33,595 | 25,731 | 12,680 | — | — | — | — | — | — | |
| Income Taxes | 6,885 | 5,091 | 2,090 | — | — | — | — | — | — | |
| Consolidated Net Income | 26,712 | 20,640 | 10,590 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 26,712 | 20,640 | 10,590 | — | — | — | — | — | — | |
| Net Income | 26,712 | 20,640 | 10,590 | — | — | — | — | — | — | |
| EPS (Recurring) | 29.89 | 23.07 | 11.76 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 29.89 | 23.07 | 11.76 | — | — | — | — | — | — | |
| EPS (Diluted) | 29.80 | 22.95 | 11.71 | — | — | — | — | — | — | |
| EBITDA | 43,305 | 31,693 | 18,807 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 42.73 | 46.83 | 65.93 | — | — | — | — | — | — | |
| Price To Sales Ratio | 14.26 | 14.81 | 15.44 | — | — | — | — | — | — | |
| Gross Margin | 83.40 | 83.04 | 81.31 | — | — | — | — | — | — | |
| Operating Margin | 49.72 | 45.56 | 37.83 | — | — | — | — | — | — | |
| Net Margin | 33.53 | 31.67 | 23.51 | — | — | — | — | — | — | |
| Shares Outstanding | 892 | 898 | 901 | — | — | — | — | — | — | |
| Market Capitalization | 1,135,926 | 965,063 | 695,572 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Jonsson Patrik | EVP & President, LLY Int'l | Aug 17 '26 | Sale | 1175.10 | 6,500 | 7,638,150 | 54,147 | Aug 18 |
| Zakrowski Donald A | SVP, Finance, & CAO | Aug 10 '26 | Sale | 1185.01 | 2,000 | 2,370,020 | 1,526 | Aug 11 |
| Hakim Anat | EVP, GC & Secretary | Aug 07 '26 | Sale | 1190.00 | 5,000 | 5,950,000 | 11,875 | Aug 10 |
| Seymour Melissa | EVP, Global Quality | Aug 01 '26 | Option Exercise | 0.00 | 981 | 0 | 1,506 | Aug 03 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | Jun 10 '26 | Sale | 1150.77 | 2,500 | 2,876,925 | 29,804 | Jun 11 |
| LILLY ENDOWMENT INC | other: Former 10% Shareholder | May 06 '26 | Sale | 995.36 | 15,828 | 15,754,537 | 91,881,150 | May 07 |
| Zakrowski Donald A | SVP, Finance, & CAO | Feb 16 '26 | Option Exercise | 0.00 | 184 | 0 | 3,607 | Feb 18 |
| Montarce Lucas | EVP & CFO | Feb 16 '26 | Option Exercise | 0.00 | 368 | 0 | 16,418 | Feb 18 |
| Custer Kenneth L. | EVP & President, Card Met Hlth | Feb 16 '26 | Option Exercise | 0.00 | 207 | 0 | 10,232 | Feb 18 |
| Brown Adrienne S | EVP, President LLY Imm | Feb 16 '26 | Option Exercise | 0.00 | 391 | 0 | 5,312 | Feb 18 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | Feb 01 '26 | Option Exercise | 0.00 | 3,394 | 0 | 29,654 | Feb 03 |
| Skovronsky Daniel | EVP, CS&PO & Pres. LRL | Feb 01 '26 | Option Exercise | 0.00 | 12,684 | 0 | 150,165 | Feb 03 |
| Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | Feb 01 '26 | Option Exercise | 0.00 | 4,108 | 0 | 24,670 | Feb 03 |
| Ricks David A | President, Chair, and CEO | Feb 01 '26 | Option Exercise | 0.00 | 31,932 | 0 | 547,098 | Feb 03 |
| Rau Diogo | EVP & CIDO | Feb 01 '26 | Option Exercise | 0.00 | 3,752 | 0 | 23,471 | Feb 03 |